26/05/2022 – AB Science today announces that Health Canada has issued a screening acceptance letter for the application of masitinib in the treatment of amyotrophic lateral sclerosis (ALS) Download PDF Post navigationPreviousPrevious post:Annual financial results as of 31 December, 2021NextNext post:Publication of results from the positive study of masitinib in severe asthma uncontrolled by oral corticosteroids in Journal of Asthma and AllergyRelated PostsAB Science receives U.S. Food and Drug Administration (FDA) authorization to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s DiseaseNovember 21, 2022AB Science receives first agencies authorizations to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s diseaseOctober 10, 2022Revenues for the first half of 2022 and update on AB Science’s activitiesSeptember 30, 2022Positive recommendation of the Data and Safety Monitoring Board to continue the Phase 2 study evaluating the antiviral activity of masitinib in Covid-19September 14, 2022AB Science announces that it has filed an application for conditional Marketing Authorization to EMA for masitinib in the treatment of ALSAugust 24, 2022Publication of results from the positive study of masitinib in severe asthma uncontrolled by oral corticosteroids in Journal of Asthma and AllergyJune 7, 2022
AB Science receives U.S. Food and Drug Administration (FDA) authorization to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s DiseaseNovember 21, 2022
AB Science receives first agencies authorizations to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s diseaseOctober 10, 2022
Positive recommendation of the Data and Safety Monitoring Board to continue the Phase 2 study evaluating the antiviral activity of masitinib in Covid-19September 14, 2022
AB Science announces that it has filed an application for conditional Marketing Authorization to EMA for masitinib in the treatment of ALSAugust 24, 2022
Publication of results from the positive study of masitinib in severe asthma uncontrolled by oral corticosteroids in Journal of Asthma and AllergyJune 7, 2022
